NCT00217529已完成1 期
A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 6
- 主要终点
- Maximum tolerated dose of erlotinib
研究概览
简要总结
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with docetaxel and carboplatin may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given together with docetaxel and carboplatin and to see how well they work in treating patients with newly diagnosed stage III or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
详细描述
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) of erlotinib when administered in combination with docetaxel and carboplatin as front-line therapy in patients with newly diagnosed stage III or IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
Secondary
- Determine the toxicity of maintenance therapy with erlotinib when administered after front-line therapy in these patients.
- Determine the proportion of patients who are able to receive the full schedule of treatment courses.
- Determine the objective response rate in patients with measurable or evaluable disease treated with this regimen.
- Determine the progression-free and overall survival of patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Maximum tolerated dose of erlotinib
次要结局
- Toxicity of maintenance therapy
- Proportion of patients who receive the full schedule of treatment courses
- Progression-free survival
- Response rate
- Overall survival
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by SurgeryBreast CancerNCT00633750Vanderbilt-Ingram Cancer Center50
已完成
1 期
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT00079053NCIC Clinical Trials Group19
已完成
2 期
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung CancerLung CancerNCT00416650Vanderbilt-Ingram Cancer Center16
已完成
2 期
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung CancerLung CancerNCT00445848SWOG Cancer Research Network89
已完成
2 期
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar CarcinomaLung CancerNCT00436332SWOG Cancer Research Network84